Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04731571 · ClinicalTrials.gov registry record
Toward High Fidelity Adaptive Radiotherapy in the Thorax
A clinical trial, sponsored by Henry Ford Health System.
- Completed
- Registry status
- 20
- Enrollment target
NCT04731571 is a clinical trial that has completed, run by Henry Ford Health System. The registered enrollment target is 20 participants.
The verdict
NCT04731571 has completed, sponsored by Henry Ford Health System.
- COMPLETED
- Registry status
- 20 participants
- Enrollment target
Study Summary
Daily adaptive radiotherapy with individualized planning margins for thoracic and pelvic cancer patients will increase the potential of reducing dose to OARs, thereby reducing treatment-related toxicities and ultimately providing these patients with a better quality of life. Thus, the overarching objective of this work is to develop a CBCT-guided adaptive workflow and to measure the benefits to patients of the adaptive treatment paradigm utilizing patient reported outcomes in a first-of-kind study.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2021-02-05 |
| Est. Completion | 2025-02-27 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04731571
The ClinicalTrials.gov registry entry for NCT04731571 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Henry Ford Health System, which has 234 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT04731571 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04731571 about?
NCT04731571 is a clinical study titled "Toward High Fidelity Adaptive Radiotherapy in the Thorax". Daily adaptive radiotherapy with individualized planning margins for thoracic and pelvic cancer patients will increase the potential of reducing dose to OARs, thereby reducing treatment-related toxicities and ultimately providing these patients with a better quality of life. Thus, the overarching ob...
What is the current status of trial NCT04731571?
This trial is currently completed. The enrollment target is 20 participants. The study started on 2021-02-05. Estimated completion is 2025-02-27.
Who is sponsoring clinical trial NCT04731571?
This trial is sponsored by Henry Ford Health System, which has 234 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.